section name header

Pronunciation

a-se-BYOO-toe-lole

Classifications

Therapeutic Classification: antiarrhythmics (class II), antihypertensives

Pharmacologic Classification: beta blockers

Indications

REMS


Action

  • Blocks stimulation of beta1–(myocardial)-adrenergic receptors. Does not usually affect beta2 (pulmonary, vascular, or uterine) receptor sites.
  • Mild intrinsic sympathomimetic activity (ISA).
Therapeutic effects:
  • Decreased heart rate.
  • Decreased BP.

Pharmacokinetics

Absorption: Well absorbed following oral administration but rapidly undergoes metabolism.

Distribution: Minimal penetration of the CNS. Crosses the placenta and enters breast milk in small amounts.

Metabolism/Excretion: Mostly metabolized to diacetolol, which is also a beta blocker.

Half-Life: 3–4 hr (8–13 hr for diacetolol).

Time/Action Profile

ROUTEONSETPEAKDURATION
PO (effect on BP)1–1.5 hr2–8 hr12–24 hr
PO (antiarrhythmic)1 hr4–6 hrup to 10 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: HF, BRADYCARDIA, hypotension, PULMONARY EDEMA

Derm: rash

EENT: blurred vision, stuffy nose

Endo: hyperglycemia, hypoglycemia

GI: constipation, diarrhea, nausea, vomiting

GU: erectile dysfunction, libido, urinary frequency

MS: arthralgia, joint pain

Neuro: fatigue, weakness, anxiety, depression, dizziness, drowsiness, insomnia, memory loss, nervousness, nightmares

Resp: bronchospasm, wheezing

Misc: drug-induced lupus syndrome

Interactions

Drug-drug:

Route/Dosage

Renal Impairment

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Sectral